A review of exenatide: Optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes

Diabetes Therapy

Volumn 3, Issue 1, 2012, Pages 1-16

  Htike, Zin Z ^a   Khunti, Kamlesh ^b   Davies, Melanie ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cardiovascular risk factors; Diabetes; Exenatide; Extended release; GLP 1 analog; Glycemic control; Hypoglycemia; Incretin mimetics; Type 2 diabetes obesity

Indexed keywords

ALOGLIPTIN; BIPHASIC INSULIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LONG ACTING DRUG; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SHORT ACTING DRUG; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; ADJUVANT THERAPY; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EXTENDED RELEASE FORMULATION; FOOD INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

EID: 84861916881     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0003-x     Document Type: Review

References (50)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
2. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
3. NICE. Type 2 Diabetes: The management of type 2 diabetes. http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf. Accessed 22 Dec 2011.
4. Nathan D, Buse J, Mayer B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
5. Nauck M, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54: 10-8.
6. Bhashyam S, Fields AV, Paterson B, et al. Glucagonlike peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxidedependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail. 2010;3: 512-21.
7. Liu X, Pachori AS, Ward CA, et al. Heme oxygenase- 1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006;20: 207-16.
8. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13:302-12.
9. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation. 2008;117:2340-50.
10. Nyström T, Gonon AT, Sjöholm A, et al. Glucagonlike peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125:173-7.
11. Chilton R, Wyatt J, Nandish S, et al. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon-like peptide-1-based therapies. Am J Med. 2011;124:S35-53.
12. NICE. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.2011. http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf. Accessed 22 Dec 2011.
13. ® (exenatide 2 mg powder and solvent for prolonged release suspension for injection) marketing authorisation press release. 2011.http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1576430. Accessed 22 Dec 2011.
14. De Fronzo RA, Ratner RE, Han J, et al. Effectsofexenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
15. Buse JB, Henry RR, Han JJ, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
16. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
17. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-47.
18. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-86.
19. Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007;146:477-85.
20. Liutkus J, Rosas GJ, Norwood P, et al. A placebocontrolled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12: 1058-65.
21. Pinelli NR, Cha R, Brown MB, et al. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother. 2008;42:1541-51.
22. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559-69.
23. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153-62.
24. Bunck M, Diamant M, Corner A, et al. One year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin treated type 2 diabetic patients. Diabetes Care. 2009;32:762-8.
25. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, twoperiod, crossover noninferiority trial. Clin Ther. 2007;29:2333-48.
26. Nauck M, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-67.
27. Buse JB, Bergenstel RM, Glass LC, et al. Use of twice daily exenatide in basal insulin-treated patients with type 2 diabetes. A randomised controlled trial. Ann Intern Med. 2011;154:1-10.
28. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab. 2011;13:703-10.
29. Yoon NM, Cavaghan MK, Brunelle RL, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over 2 years in an academic endocrinology outpatient setting. Clin Ther. 2009;31:1511-23.
30. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285-92.
31. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;274:39-47.
32. Larsen J, Hylleberg B, Ng K, et al. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001;24:1416-21.
33. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-50.
34. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct tometformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-9.
35. Diamant M, Goal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-43.
36. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as a monotherapy in drug-nai{dotless}̈ve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252-8.
37. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patientswith type 2 diabetes. J Clin EndocrinolMetab. 2011;96:1301-10.
38. Buse J, Nauck M, Frost T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION 6): a randomised, open-label study. Diabetologia. 2011;54:S38.
39. Buse J, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255-61.
40. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
41. The ACCORD study group, Gerstein HC, Miller ME, et al. Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
42. The ADVANCE collaborative group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;48:2560-72.
43. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44:2107-14.
44. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499-504.
45. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLinkTM database. Diabetes Care. 2010;34:90-5.
46. Peskin B, Shcheprov A, Boye K, et al. Cardiovascular outcomes associated with a new once-weekly GLP-q receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab. 2011;13:921-7.
47. ClinicalTrials.gov. EXenatide Study ofCardiovascular Event Lowering (EXSCEL). http://clinicaltrials.gov/ct2/show/NCT01144338. Accessed 22 Dec 2011.
48. Hirata K, Kume S, Araki S, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380: 44-9.
49. Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23: 334-9.
50. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review andmeta-analysis. JAMA. 2007;298:194-206.